0001213900-25-050961.txt : 20250604 0001213900-25-050961.hdr.sgml : 20250604 20250604062141 ACCESSION NUMBER: 0001213900-25-050961 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250604 DATE AS OF CHANGE: 20250604 EFFECTIVENESS DATE: 20250604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CollPlant Biotechnologies Ltd CENTRAL INDEX KEY: 0001631487 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-547984 FILM NUMBER: 251021844 BUSINESS ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 BUSINESS PHONE: 972-73-232-5600 MAIL ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20190620 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Biotechnologies Ltd. DATE OF NAME CHANGE: 20190619 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20150122 D 1 primary_doc.xml X0708 D LIVE 0001631487 CollPlant Biotechnologies Ltd 4 OPPENHEIMER, WEIZMANN SCIENCE PARK REHOVOT L3 ISRAEL 7670104 +972 73 232 5600 ISRAEL None CollPlant Holdings Ltd. CollPlant Biotechnologies Ltd. Corporation true Yehiel Tal COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Director Chief Executive Officer and Director Eran Rotem COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Deputy Chief Executive Officer and Chief Financial Officer Oren Fahimipoor COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Operations Philippe Bensimon COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Regulatory Affairs and Quality Assurance Elana Gazal COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Research and Development Hadas Dreiher Horowitz COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Human Resources Roger Dreiher Pomerantz COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Abraham Havron COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Elan Penn COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Joseph Zarzewsky COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Hugh Evans COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Alisa Lask COLLPLANT BIOTECHNOLOGIES LTD. 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Other Health Care Decline to Disclose 06b false 2025-05-29 false true true false 0 H.C. Wainwright & Co. LLC 000000375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 CA CALIFORNIA FL FLORIDA IL ILLINOIS NY NEW YORK true 3870006 3870006 0 The warrants and shares underlying the warrants, were issued in connection with an offering of (i) 1,200,002 ordinary shares issued in a registered direct offering, and (ii) unregistered warrants to purchase 1,272,002 ordinary shares. false 4 252000 0 H.C. Wainwright is also entitled to 1.0% of the gross proceeds as management fee, $85,000 for non-accountable expenses, $15,950 for clearing fees and warrants to purchase 72,000 ordinary shares exercisable at $3.75 per share for 3.5 years. 0 The Company intends to use the net proceeds for general corporate purposes, which may include supporting the work with its business partner regarding one of its product candidates, funding working capital and funding research and development. false CollPlant Biotechnologies Ltd /s/ Eran Rotem Eran Rotem Deputy Chief Executive Officer and Chief Financial Officer 2025-06-04